Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Zerafil (Omalizumab) vs Xolair in Allergic Asthma
NCT05813470Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in allergic asthma (2 arms), sponsored by CinnaGen. Primary endpoint: Rate of protocol-defined asthma exacerbations at 28 weeks. Started Jan 2021; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT05813470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813470.